Shared on 06 Nov 25
Fair value Decreased 13%LFCR: Future Program Wins Will Drive Upside As Pipeline Expands
Analysts have lowered their fair value estimate for Lifecore Biomedical from $10.00 to $8.75 per share. They cited moderated growth assumptions and the need for additional program wins to drive valuation expansion.
Shared on 23 Apr 25
Fair value Decreased 29%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
AnalystConsensusTarget has increased revenue growth from 5.1% to 12.6% and decreased future PE multiple from 29.2x to 23.6x.
Shared on 09 Apr 25
Fair value Increased 0.40%AnalystConsensusTarget has decreased revenue growth from 8.1% to 5.1% and increased future PE multiple from 26.3x to 29.2x.
Shared on 02 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Decreased 1.20%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 11 Mar 25
Fair value Decreased 1.20%AnalystConsensusTarget has decreased revenue growth from 10.9% to 8.1%, increased future PE multiple from 23.0x to 26.4x and decreased shares outstanding growth rate from 0.2% to 0.1%.